Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

51.89USD
20 Sep 2017
Change (% chg)

-- (--)
Prev Close
$51.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,725,061
52-wk High
$52.60
52-wk Low
$37.38

Latest Key Developments (Source: Significant Developments)

Abbott announces extension of cash tender offer
Monday, 18 Sep 2017 08:01am EDT 

Sept 18 (Reuters) - Abbott Laboratories :Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc..Abbott Laboratories - ‍ offer will now expire at 11:59 p.m., New York City time, on Friday, Sept. 29, 2017​.  Full Article

Quidel announces revised agreement for pending acquisition of Alere’s business
Monday, 18 Sep 2017 07:00am EDT 

Sept 18 (Reuters) - Quidel Corp :Quidel announces revised agreement for its pending acquisition of Alere’s B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter Analyzers.Quidel - ‍ previously announced transaction to purchase Triage Meterpro cardiovascular and toxicology assets from alere remains substantially unchanged​.Quidel-‍revised agreement provides co direct commercial responsibility after purchase for all sales globally of Alere's BNP assay unit run on Beckman Analyzers​.Quidel Corp - ‍ transactions will be funded through a combination of cash on hand and committed financing​.Quidel Corp - ‍total cash consideration for Alere's Triage MeterPro assets and beckman coulter bnp sales​ will now be up to $680 million.Quidel Corp - ‍ believe co is on track to close acquisition of Triage and BNP businesses within 30 days of Abbott's close of Alere acquisition​.Quidel- deal consideration of $680 million made of $400 million purchase price for triage business, $40 million in contingent consideration for eea bnp business.Quidel- deal consideration of $680 million also comprised of $240 million in deferred consideration for rest-of-world BNP business​.  Full Article

Abbott sets quarterly dividend of $0.265 per share
Thursday, 14 Sep 2017 12:30pm EDT 

Sept 14 (Reuters) - Abbott ::Sets quarterly dividend of $0.265 per share.  Full Article

Abbott Laboratories says ‍NHS Business Services Authority approved listing on Drug Tariff for FreeStyle Libre system
Wednesday, 13 Sep 2017 07:01am EDT 

Sept 13 (Reuters) - Abbott Laboratories :Abbott Laboratories - ‍NHS Business Services Authority approved listing on Drug Tariff for FreeStyle Libre system for people with diabetes using insulin​.Abbott Laboratories - ‍ from Nov. 1, 2017 FreeStyle Libre flash glucose monitoring technology will be available for reimbursement via NHS ​.  Full Article

Abbott initiates study of AMPLATZER device to correct congenital heart defect in newborns
Wednesday, 30 Aug 2017 11:56am EDT 

Aug 30 (Reuters) - Abbott Laboratories :Abbott initiates ground-breaking U.S. pivotal study of AMPLATZER device to correct common congenital heart defect in newborns.‍Study of AMPLATZER device​ will enroll approximately 50 patients at up to 10 centers across United States.  Full Article

U.S. FDA says has approved St. Jude medical’s firmware update ‍​
Tuesday, 29 Aug 2017 01:03pm EDT 

Aug 29 (Reuters) - U.S. Food and Drug Administration::U.S. FDA says has approved St. Jude medical’s firmware update ‍​.  Full Article

Enzo Biochem says federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences v. Abbott Laboratories ​
Wednesday, 16 Aug 2017 06:18am EDT 

Aug 16 (Reuters) - Enzo Biochem Inc ::Enzo Biochem says ‍a federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences, Inc. v. Abbott Laboratories - sec filing​.U.S. Court's order ‍denies summary judgment that U.S. Patent no. 8,097,405 is invalid for lack of written description.‍U.S. Court's order also granted summary judgment that U.S. Patent no. 8,097,405​ is invalid for lack of enablement.‍Enzo "disagrees" with court's decision, and is exploring options for review of decision​.  Full Article

Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc
Monday, 14 Aug 2017 08:00am EDT 

Aug 14 (Reuters) - Abbott Laboratories :Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc.Abbott Laboratories - ‍offer was previously scheduled to expire on Aug. 11, 2017 and will now expire, on Thursday, Aug. 31, 2017​.  Full Article

Abbott Laboratories says entered into term loan agreement with lenders
Monday, 31 Jul 2017 05:42pm EDT 

July 31 (Reuters) - Abbott Laboratories ::Abbott Laboratories - on july 31, co, entered into term loan agreement with lenders and Bank Of America, N.A., as administrative agent.Abbott Laboratories - loans will be made in a single borrowing and mature and be payable in full 5 years after date of such borrowing.Abbott Laboratories says term loan agreement provides co ability to borrow up to $2.8 billion on unsecured basis to finance Alere acquisition - sec filing.  Full Article

Abbott Q2 adjusted EPS $0.62 from continuing operations excluding items
Thursday, 20 Jul 2017 07:45am EDT 

July 20 (Reuters) - Abbott Laboratories ::Abbott reports second-quarter 2017 results.Q2 adjusted earnings per share $0.62 from continuing operations excluding items.Q2 gaap earnings per share $0.15 from continuing operations.Q2 earnings per share view $0.61 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $2.43 to $2.53 from continuing operations.Sees FY 2017 gaap earnings per share $1.03 to $1.13 from continuing operations.Q2 sales $6.6 billion versus I/B/E/S view $6.63 billion.Abbott Laboratories - ‍second-quarter worldwide sales of $6.6 billion increased 24.4 percent on a reported basis​.Abbott Laboratories qtrly total diagnostics sales $‍1,273​ million, up 3.8 percent on a reported basis.Abbott Laboratories - Q2 total vascular sales $731‍​ million, up 6.6 percent on a reported basis.Abbott Laboratories - qtrly total pediatric sales $‍​987 million, up 1.4 percent on a reported basis.Q2 total nutrition sales $1,731 million, down 0.6 percent on a reported basis.FY 2017 earnings per share view $2.47 -- Thomson Reuters I/B/E/S.Says ‍raises full-year 2017 EPS guidance range for continuing operations​.Abbott Laboratories - ‍sales growth in quarter impacted by purchasing patterns associated with implementation of new goods and services tax system in India​.  Full Article

BRIEF-Alere announces intent to voluntarily delist Series B Convertible Perpetual Preferred Stock from the NYSE

* Alere announces intent to voluntarily delist Series B Convertible Perpetual Preferred Stock from the NYSE conditioned upon the completion of its acquisition by Abbott